Chalcogen Bonded Directly To A Ring Carbon Of The 1,3-diazole Ring Patents (Class 546/273.7)
-
Patent number: 7745466Abstract: The present invention relates to a novel form of the (?)-enantiomer of 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole, i.e. S-omeprazole. More specifically, it relates to a novel form of the magnesium salt of the S-enantiomer of omeprazole trihydrate. The present invention also relates to processes for preparing such a form of the magnesium salt of S-omeprazole and pharmaceutical compositions containing it. Furthermore, the present invention also relates to new intermediates used in the process.Type: GrantFiled: September 11, 2007Date of Patent: June 29, 2010Assignee: AstraZeneca ABInventors: Hanna Cotton, Anders Kronström, Anders Mattson, Eva Möller
-
Publication number: 20100160639Abstract: A process for preparation of optically pure or optically enriched enantiomers of sulphoxide compounds of formula (I), such as omeprazole and structurally related compounds, as well as their salts and hydrates.Type: ApplicationFiled: October 5, 2006Publication date: June 24, 2010Applicant: Lupin LimitedInventors: Girij Pal Singh, Himanshu Madhav Godbole, Narotham Maddireddy, Suhas Ganpat Tambe, Sagar Purushottam Nehate, Harischandra Sambhaji Jadhav
-
Publication number: 20100160380Abstract: Therapeutic salt compositions and methods are disclosed herein.Type: ApplicationFiled: July 27, 2009Publication date: June 24, 2010Inventors: Mark P. Rubino, Gyorgy F. Ambrus
-
Publication number: 20100152125Abstract: One aspect of the invention relates to a method of treating or preventing a neurodegenerative disease, comprising the step of administering to a patient in need thereof a therapeutically effective amount of an inhibitor of the formation of advanced glycation end products. Another aspect of the invention relates to a proteasome activity-based screening assay to select compounds which may be useful for treating or preventing a neurodegenerative disease, and the materials used therein. Yet another aspect of the invention relates to molecules, and methods of use thereof, which bind at or adjacent to SOD-I Trp32, including molecules that bind in a site adjacent to SOD-I Trp32 whether or not it is oxidized, for treating or preventing neurodegenerative disease.Type: ApplicationFiled: March 20, 2008Publication date: June 17, 2010Applicant: Brandeis UniversityInventors: Jeffrey N. Agar, Gregory A. Petsko, Dagmar Ringe, Walter R.P. Novak
-
Patent number: 7737282Abstract: A novel crystal of (R)-2-[[[3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridinyl]methyl]sulfinyl]-1H-benzimidazole or a salt thereof of the present invention is useful for an excellent antiulcer agent.Type: GrantFiled: February 26, 2009Date of Patent: June 15, 2010Assignee: Takeda Pharmaceutical Company LimitedInventors: Akira Fujishima, Isao Aoki, Keiji Kamiyama
-
Publication number: 20100145057Abstract: The present invention describes novel prodrugs of formula (I) or their salts, process of preparation and uses thereof.Type: ApplicationFiled: March 14, 2008Publication date: June 10, 2010Applicant: SUN PHARMA ADVANCED RESEARCH COMPANY LTD.Inventors: Rajamannar Thennati, Biswajit Samanta, Ranjan Kumar Pal, Srinivasu Kilaru, Jignesh Jivani, Savajibhai Anil Kumbhani, Jay Prakashchandra Adhyapak
-
Publication number: 20100145058Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.Type: ApplicationFiled: February 9, 2010Publication date: June 10, 2010Inventors: Yatendra KUMAR, Mahavir Singh Khanna, Mohan Prasad
-
Publication number: 20100137607Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.Type: ApplicationFiled: February 9, 2010Publication date: June 3, 2010Inventors: Yatendra KUMAR, Mahavir Singh Khanna, Mohan Prasad
-
Publication number: 20100125143Abstract: Process for the preparation of (R)-2-[[[3-methyl-4(2,2,2-trifluoroethoxy)-2-piridyl]methyl]sulfinyl]benzimidazole (Dexlansoprazole) and new intermediates useful in its preparation.Type: ApplicationFiled: November 17, 2009Publication date: May 20, 2010Applicant: DIPHARMA FRANCIS S.r.I.Inventors: Emanuele ATTOLINO, Vittorio Lucchini
-
Publication number: 20100125142Abstract: An improved process for the preparation of (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole of Formula I, (I) with high enantiomeric excess from racemic mixture.Type: ApplicationFiled: May 30, 2008Publication date: May 20, 2010Inventors: Shankar Reddy Budidet, Brajesh Kumar Sinha, Somappa Somannavar Yallappa, Senthil Kumar Natarajan, Ramesh Dandala, Sivakumaran Meenakshisunderam
-
Publication number: 20100113527Abstract: Provided are crystalline forms of dexLansoprazole, as well as processes for the preparation thereof.Type: ApplicationFiled: September 30, 2009Publication date: May 6, 2010Inventors: Jacob RENDELL, Ariel MITTELMAN, Rinat MOSHKOVITS-KAPTSAN, Sergei FINE, Ana KWOKAL, Tamas KOLTAI
-
Publication number: 20100113524Abstract: The compounds of the formulas (I), (II), (III) and (IV), where the symbols are as defined in the specification are prodrugs of proton pump inhibitors. The R4 group includes at least one acidic group or its pharmaceutically acceptable salt, and the compound having the R4 group have improved aqueous solubility, stability in plasma and improved bioavailability.Type: ApplicationFiled: September 15, 2007Publication date: May 6, 2010Inventors: Michael E. Garst, George Sachs, Jai Moo Shin
-
Publication number: 20100093804Abstract: The present invention relates to a novel and stable crystalline polymorph of lansoprazole, a process for its preparation and to a pharmaceutical composition comprising it. Thus, for example, lansoprazole crude is dissolved in methanol at 20-30° C. followed by stirring and the solution is cooled to 0-10° C. The resulting solution is stirred for 1 hour to 1 hour 30 minutes at 0-10° C., the solid is filtered and then dried to give lansoprazole crystalline form III.Type: ApplicationFiled: December 7, 2006Publication date: April 15, 2010Applicant: HETERO DRUGS LIMITEDInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy
-
Publication number: 20100092426Abstract: Inhibitors of RSV replication of formula (I) the addition salts and stereochemically isomeric forms thereof, wherein Q is hydrogen, C1-6alkyl optionally substituted with a heterocycle or Q is C1-6alkyl substituted with both —OR4 and a heterocycle; wherein said heterocycle is oxazolidine, thiazolidine, 1-oxo-thiazolidine, 1,1-dioxothiazolidine, morpholinyl, thiomorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxothiomorpholinyl, hexahydrooxazepine, hexahydro-thiazepine, 1-oxo-hexahydrothiazepine, 1,1-dioxo-hexahydrothiazepine, pyrrolidine, piperidine, homopiperidine, piperazine; which heterocyle may be substituted with 1-2 substituents; each Alk is C1-6alkanediyl; R1 is Ar2 or optionally substituted piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, pyridyl, pyrazinyl, pyridazinyl, pyrimidinyl, furanyl, tetrahydro-furanyl, thienyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, isothiazolyl, pyrazolyl, isoxazolyl, oxadiazolyl, quinolinyl, quinoxalinyl, benzofuranyl, benzothienyl, benzimidazolyl, benzoxazolyl, benzthType: ApplicationFiled: June 20, 2006Publication date: April 15, 2010Inventors: Jean-Francois Bonfanti, Philippe Muller, Jérôme Michel Claude Fortin, Frédéric Marc Maurice Doublet
-
Publication number: 20100087652Abstract: The present invention discloses a process for preparing a magnesium salt of S-omeprazole. The S-omeprazole salt preferably has a water content below about 4.8% by weight, a magnesium content of about 3.4-4.0% by weight, calculated on the weight of anhydrous, solvent free S-omeprazole magnesium, and has an optical purity of at least about 85% entantiomeric excess (“e.e.”). In addition, the present invention provides a magnesium salt of S-omeprazole which is substantially free of neutral omeprazole, meaning that the product contains less than about 3% by weight of a sum of neutral S-omeprazole and neutral omeprazole. Moreover, the S-omeprazole magnesium according to the invention preferably has assay of related substances and degradation products of less than about 0.1% by weight as determined by high performance liquid chromatography (HPLC).Type: ApplicationFiled: April 1, 2009Publication date: April 8, 2010Applicant: LEK PHARMACEUTICALS D.D.Inventors: Lidija Vranicar Savanovic, Dejan Mandic, Renata Toplak Casar
-
Publication number: 20100081643Abstract: Novel compounds of the structural formula (I) are activators of AMP-protein kinase and are useful in the treatment, prevention and suppression of diseases mediated by the AMPK-activated protein kinase. The compounds of the present invention are useful in the treatment of Type 2 diabetes, hyperglycemia, metabolic syndrome, obesity, hypercholesterolemia, and hypertension.Type: ApplicationFiled: September 21, 2009Publication date: April 1, 2010Inventors: BRETT C. BOOKSER, Qun Dang, Tony S. Gibson, Hongjian Jiang, De Michael Chung, Jianming Bao, Jinlong Jiang, Andy Kassick, Ahmet Kekec, Ping Lan, Huagang Lu, Gergely M. Makara, F. Anthony Romero, Iyassu Sebhat, David Wilson, Dariusz Wodka
-
Publication number: 20100076025Abstract: The present invention relates to a process for removing an organic solvent from a salt of omeprazole, in particular a magnesium salt of omeprazole, a composition comprising a salt of omeprazole, in particular a magnesium salt of omeprazole obtainable by such a process, and pharmaceutical compositions comprising said composition or a salt of omeprazole, in particular a magnesium salt of omeprazole, in particular where omeprazole is S-omeprazole.Type: ApplicationFiled: January 9, 2008Publication date: March 25, 2010Applicant: LEK PHARMACEUTICALS D.D.Inventors: Dejan Mandic, Renata Toplak Casar
-
Patent number: 7683080Abstract: The present invention provides a stable 2-(2-pyridylmethyl) sulfinyl-1H-benzimidazole (lansoprazole) comprising either greater than 500 ppm and not more than about 3,000 ppm water or greater than 200 ppm and not more than about 5,000 ppm alcohol, or both. The present invention provides a method of preparing a stable lansoprozole as well as a pharmaceutical composition containing same. The present invention further provides a method of purifying lansoprazole that is substantially free of sulfone and sulfide derivatives.Type: GrantFiled: November 18, 2003Date of Patent: March 23, 2010Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Anita Liberman, Claude Singer, Irena Veinberg
-
Patent number: 7683178Abstract: A process for the manufacture of omeprazole or esomeprazole from pyrmethyl alcohol via pyrmethyl chloride and pyrmetazole characterized in that the whole reaction sequence is carried out without any isolation or purification of intermediates. Further, the reaction is carried out in a solvent system common for the whole reaction sequence and inert to the reactants formed during the process and used in the process and comprises a water immiscible organic solvent and a specified amount of water.Type: GrantFiled: May 16, 2007Date of Patent: March 23, 2010Assignee: AstraZeneca ABInventor: Anders Gustavsson
-
Patent number: 7683177Abstract: The present invention provides a process comprising admixing a thioether with about 1.05 to about 1.6 molar equivalents of an active chlorine-containing oxidant, preferably sodium hypochlorite, and about 2.5 to about 5.0 molar equivalents of an alkali metal base; and recovering a sulfoxide that is preferably pantoprazole, lansoprazole, omeprazole, or rabeprazole. The process may further comprise contacting the sulfoxide with a source of sodium ions, preferably sodium hydroxide, to produce the sodium salt of the sulfoxide. The invention also relates to novel chlorinated derivatives of pantoprazole including 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chloromethyl]sulfinyl]-1H-benzimidazole and 5-(difluoromethoxy)-2-[[(3,4-dimethoxy-2-pyridinyl)-chlorohydroxymethyl]sulfinyl]-1H-benzimidazole and processes for making them. The invention also relates to processes of quantifying and identifying a compound other than pantoprazole in a mixture of pantoprazole and at least one other compound.Type: GrantFiled: June 10, 2004Date of Patent: March 23, 2010Assignee: Teva Pharmaceutical Industries LtdInventors: Viviana Braude, Nina Finkelstein, Kobi Chen, Gideon Pilarsky, Anita Liberman, Claude Singer, Yuriy Raizi
-
Patent number: 7678816Abstract: The present invention provides a stable 2-(2-pyridylmethyl)sulfinyl-1H-benzimidazole (lansoprazole) and a method for stabilizing lansoprazole by use of a weakly basic material. The present invention also provides a method for the preparation of a stable lansoprazole.Type: GrantFiled: February 5, 2004Date of Patent: March 16, 2010Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Claude Singer, Anita Liberman, Irena Veinberg
-
Publication number: 20100056515Abstract: There is provided a compound of the formula (I): wherein R1 is an optionally substituted C1-10 alkyl; R2 is H, or a C1-6 alkyl which may be substituted with 1 to 3 substituents; R3 is a 5- or 6-membered aromatic group which may be substituted with 1 to 5 substituents, wherein the 5- or 6-membered aromatic group may be fused with a 5- or 6-membered ring which may be substituted with 1 to 3 C1-6 alkyls; R4 is a hydrogen, a halogen, a hydroxy, a cyano, a C1-6 alkyl or a C1-6 alkoxy; Z is —O—, —S—, —SO—, —SO2—, or —NR5— wherein R5 is a hydrogen or a C1-6 alkyl; or a salt thereof or a prodrug thereof, which have CRF receptor antagonist activity and use thereof.Type: ApplicationFiled: October 24, 2007Publication date: March 4, 2010Inventors: Kazuyoshi Aso, Michiyo Mochizuki, Takuto Kojima, Katsumi Kobayashi, Scott Alan Pratt, Albert Charles Gyorkos, Christopher Peter Corrette, Suk Young Cho
-
Patent number: 7662968Abstract: The invention relates to a process for preparing lansoprazole. It is also directed to lansoprazole having a specific surface area and a pharmaceutical composition comprising lansoprazole.Type: GrantFiled: November 8, 2005Date of Patent: February 16, 2010Assignee: KRKA tovarna zdravil, d.d..Inventors: Berta Kotar-Jordan, Franc Vre{hacek over (c)}er, Mojca {hacek over (S)}egula {hacek over (Z)}akelj, Gregor Ritlop
-
Publication number: 20100022778Abstract: It is an object of the present invention to provide a process for the production on an industrial scale of a compound (1) or a salt thereof. There is provided a process for the production of compound (1) represented by the formula or a salt thereof: (wherein R1 and R3 independently represents a hydrogen atom or a methyl group), the process comprising the steps of: (a) reacting together a compound (3T) represented by the formula: (wherein X1 represents a leaving group, and R1 and R3 are defined as above) and (2,2-dimethyl-1,3-dioxan-5-yl)methanol represented by the formula or a salt thereof: so as to produce a compound (2T) represented by the formula (wherein R1 and R3 are defined as above); and (b) reacting the compound represented by above formula (2T) with an oxidizing agent.Type: ApplicationFiled: October 11, 2007Publication date: January 28, 2010Inventors: Atsushi Kamada, Daisuke Iida, Hiroki Terauchi
-
Publication number: 20100022779Abstract: The invention relates to compounds of formula 1 and formula 10 and to compositions comprising these compounds and methods of treating gastrointestinal disorders by administering these compounds.Type: ApplicationFiled: July 21, 2009Publication date: January 28, 2010Applicant: NYCOMED GMBHInventors: Bernhard Kohl, Bernd Müller, Dieter Haag, Wolfgang-Alexander Simon, Karl Zech, Michael David, Oliver Von Richter, Felix Huth
-
Publication number: 20100016606Abstract: A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.Type: ApplicationFiled: September 28, 2009Publication date: January 21, 2010Applicants: DR. REDDY'S LABORATORIES LIMITED, DR. REDDY'S LABORATORIES, INC.Inventors: Manne Satyanarayana Reddy, Muppa Kishore Kumar, Koilkonda Purandhar, Keshaboina Sreenath
-
Publication number: 20100016605Abstract: A one-pot process for the preparation of pantoprazole sodium by reacting 2-chloro methyl 3,4-dimethoxy pyridine hydrochloride with 2-mercapto-5-difluoromethoxy benzimidazole in an organic solvent system in presence of a phase transfer catalyst and further treating with aqueous sodium hypohalite solution comprising sodium hydroxide to obtain pantoprazole sodium in high yield and purity. The process for conversion of pantoprazole sodium to pantoprazole sodium sesquihydrate and also pantoprazole sodium monohydrate are also disclosed herein.Type: ApplicationFiled: December 15, 2005Publication date: January 21, 2010Applicant: CIPLA LIMITEDInventors: Rajendra Narayanrao Kankan, Srinivas Laxminarayan Pathi
-
Publication number: 20100016370Abstract: There is provided a process for preparing purified esomeprazole magnesium, comprising the steps of: providing esomeprazole magnesium; contacting said esomeprazole magnesium with a non-solvent comprising an aqueous component up to a maximum content defined by water saturation in the non-solvent; and recovering purified esomeprazole magnesium formed from the contacting step. The process is particularly suitable to obtain esomeprazole magnesium dihydrate, especially form A. The esomeprazole magnesium obtained is remarkably pure, stable and is resistant to form interchangeability.Type: ApplicationFiled: July 21, 2009Publication date: January 21, 2010Applicant: LEK PHARMACEUTICALS D.D.Inventor: Renata Toplak Casar
-
Publication number: 20100015717Abstract: The present invention relates generally to novel protein modification reagents for fractionation and quantitative (differential) profiling of proteins in a complex mixture. The reagents react with amino acids or other protein components or structures and function as mass tags. The present invention provides methods of making the protein modification reagents and methods of using the protein modification reagents for quantitative analysis of proteins.Type: ApplicationFiled: February 23, 2009Publication date: January 21, 2010Applicant: PPD BIOMARKER DISCOVERY SCIENCES LLCInventors: Rajendra Singh, Haihong Zhou
-
Publication number: 20100010047Abstract: The invention relates to compounds of formula 1 and formula 10 and to compositions comprising these compounds and methods of treating gastrointestinal disorders by administering these compounds.Type: ApplicationFiled: August 31, 2009Publication date: January 14, 2010Inventors: Bernhard Kohl, Bernd MÜLLER, Dieter Haag, Wolfgang-Alexander Simon, Karl Zech, Michael David, Oliver Von Richter, Felix Huth
-
Publication number: 20100010230Abstract: The present invention relates to an improved process for the preparation of Lansoprazole of formula (I). More particularly, the present invention relates to a method for the purification of crude Lansoprazole in a solvent in presence of an alkali salt of an organic acid or in presence of an organic base such as piperidine or imidazole.Type: ApplicationFiled: September 21, 2007Publication date: January 14, 2010Applicant: Orchid Chemicals & Pharmaceuticals LimitedInventors: Thangavel Arulmoli, Siripragada Mahender Rao, Krishna Sumanth Peraka, Ariyamuthu Sundara Selvan
-
Patent number: 7638633Abstract: A process for preparation of rabeprazole sodium comprising oxidation of wet or dry rabeprazole sulphide with sodium hypohalite in water or a mixture of water and water miscible solvent using alkali metal hydroxide and catalyst is disclosed herein. The present invention also discloses process for preparation of rabeprazole sulphide.Type: GrantFiled: February 21, 2006Date of Patent: December 29, 2009Assignee: Cipla LimitedInventors: Srinivas Laxminarayan Pathi, Rajendra Narayanrao Kankan, Dharmaraj Ramachandra Rao
-
Patent number: 7638634Abstract: The present invention relates to a novel amorphous form of esomeprazole hydrate, to a process for its preparation and to a pharmaceutical composition containing it. Thus, tetrahydrofuran and water are added to esomeprazole potassium salt at 25-30° C., cooled to 20° C. and then the pH is adjusted to 7.5-8.0 with acetic acid. The reaction mass is cooled to 5° C., stirred for 2 to 3 hours at 0-5° C., filtered the mass, washed with chilled mixture of water and tetrahydrofuran (2:1) and again washed with water. The wet cake is dried at 30-35° C. under vacuum to reach the moisture content to 25-30%. The solid is again dried in rotovapour at 25-30° C. under nitrogen atmosphere to give amorphous esomeprazole hydrate.Type: GrantFiled: March 6, 2009Date of Patent: December 29, 2009Assignee: Hetero Drugs LimitedInventors: Bandi Parthasaradhi Reddy, Kura Rathnakar Reddy, Rapolu Raji Reddy, Dasari Muralidhara Reddy
-
Publication number: 20090312314Abstract: The present invention is concerned with novel sulfonamides of formula wherein R1, R2, R3, R4, R5, Ar, Ar1, Ar2, n, o and p are as described in the description and claims. The compounds are orexin receptor antagonists that may be useful in the treatment of disorders, in which orexin pathways are involved.Type: ApplicationFiled: June 10, 2009Publication date: December 17, 2009Inventors: Henner Knust, Matthias Nettekoven, Emmanuel Pinard, Olivier Roche, Mark Rogers-Evans
-
Publication number: 20090306393Abstract: The present invention relates to an improved process for the preparation of pantoprazole free from overoxidation impurities. The process enables better control of the process and therefore the quality of the products obtained, avoiding the formation of impurities.Type: ApplicationFiled: December 14, 2006Publication date: December 10, 2009Inventors: Blazenko Bajic, Drazen Cavuzic, Nafis Defterdarovic, Vesna Miskovic Klecar, Igor Sostaric
-
Patent number: 7629361Abstract: The invention relates to (?)-pantoprazole magnesium and its hydrates and to medicaments comprising these compounds.Type: GrantFiled: July 26, 2003Date of Patent: December 8, 2009Assignee: NYCOMED GmbHInventors: Wolfgang Kromer, Bernd Müller, Stefan Postius, Wolfgang-Alexander Simon, Ernst Sturm, Guido Hanauer
-
Publication number: 20090298884Abstract: A strontium salt of esomeprazole is provided. A process for preparing a strontium salt of esomeprazole is also provided comprising reacting esomeprazole free base or a sodium, potassium or lithium salt of esomeprazole with a strontium source in one or more solvents.Type: ApplicationFiled: May 2, 2006Publication date: December 3, 2009Applicant: GLENMARK GENERICS LTD.Inventors: Shekhar Bhaskar Bhirud, Nitin Sharad Chandra Pradhan, Bobba Venkata Siva Kumar, Pravin Bhalchandra Kulkarni
-
Publication number: 20090292120Abstract: The present invention provides a compound that has superior gastric acid secretion inhibitory action, ample long-lasting gastric acid secretion inhibitory action, and is able to maintain intragastric pH at a high level for an extended period of time, making it useful as a therapeutic or prophylactic agent for diseases or symptoms caused by gastric acid, as well as an active form of this compound (form to which the compound is converted in the body following administration thereof) in the form of a compound represented by general formula (1a) (wherein R2 represents a group represented by formula (I) or the like, and R1, R3, W1 and X? are as defined in the description).Type: ApplicationFiled: October 11, 2007Publication date: November 26, 2009Inventors: Masato Ueda, Daisuke Iida, Sachiko Kikuchi, Masaharu Gotoda
-
Patent number: 7622588Abstract: The present invention provides a method for preparing a substantially pure lansoprazole containing less than about 0.2% (wt/wt) impurities including sulfone/sulfide derivatives. The present invention also provides a process for recrystallizing lansoprazole to obtain a lansoprazole containing less than about 0.1% (wt/wt) water.Type: GrantFiled: March 18, 2005Date of Patent: November 24, 2009Assignee: Teva Pharmaceutical Industries Ltd.Inventors: Claude Singer, Anita Liberman, Irena Veinberg, Nina Finkelstein, Tamar Nidam
-
Publication number: 20090274755Abstract: The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl) methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R and S enantiomers is formed to an enantiomeric excess.Type: ApplicationFiled: July 7, 2009Publication date: November 5, 2009Inventors: Kenneth S. Wheelock, Louis A. Piccone
-
Patent number: 7612098Abstract: A hydrate of esomeprazole magnesium in the form of an amorphous solid is provided. Methods of preparation and use of, as well as formulation containing the hydrate of esomeprazole magnesium in the form of an amorphous solid are also provided.Type: GrantFiled: August 28, 2003Date of Patent: November 3, 2009Assignees: Dr. Reddy's Laboratories Limited, Dr. Reddy's Laboratories, Inc.Inventors: Manne Satyanarayana Reddy, Muppa Kishore Kumar, Koilkonda Purandhar, Keshaboina Sreenath
-
Publication number: 20090264658Abstract: It is an object of the present invention to provide (1) a process for manufacturing alkali metal salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole which are useful as gastric acid secretion inhibitors, anti-ulcer agents and other drugs and (2) salts of 2-[{4-(3-methoxypropoxy)-3-methylpyridin-2-yl}methylsulfinyl]-1H-benzimidazole with amines which are intermediates for the production of the alkali metal salts, and a process for manufacturing the same. According to the present invention, disclosed are salts represented by the following formula (I): (wherein A+ represents an isopropylammonium ion, sec-butylammonium ion or cyclopentylammonium ion).Type: ApplicationFiled: June 24, 2009Publication date: October 22, 2009Inventors: Hiroyuki YOKOI, Masanori MIZUNO, Toyokazu HAGA
-
Patent number: 7605268Abstract: A process for preparation of a compound of formula (I), both as the isomeric mixture and individual isomers, wherein Q is ?CR8— or ?N—; each R1, R2, R3, R4 is independently selected from hydrogen, halogen, hydroxy; nitro; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen or C1-C6 alkoxy; phenyl-C1-C6 alkyl; phenyl-C1-C6 alkoxy; and —N(RaRb) wherein each Ra and Rb is independently hydrogen or C1-C6 alkyl or Ra and Rb, taken together with the nitrogen atom they are linked to, form a saturated heterocyclic ring; and each R5, R6, R7, R8 is independently selected from hydrogen, halogen, hydroxy; C1-C6 alkyl optionally substituted with hydroxy; alkylthio C1-C6; C1-C6 alkoxy optionally substituted with halogen; C1-C6 alkyl-carbonyl, C1-C6 alkoxy-carbonyl, and oxazol-2-yl; comprising converting a compound of formula (IV), to said compound of formula (I), in the presence of a catalyst, if necessary in an organic solvent.Type: GrantFiled: April 20, 2007Date of Patent: October 20, 2009Assignee: Dipharma Francis s.r.l.Inventors: Pietro Allegrini, Marcello Rasparini, Gabriele Razzetti, Roberto Rossi, Gianpiero Ventimigla
-
Publication number: 20090258908Abstract: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.Type: ApplicationFiled: April 17, 2009Publication date: October 15, 2009Applicant: Hanmi Pharm. Co., Ltd.Inventors: Tae Hee HA, Hee Sook OH, Won Jeoung KIM, Chang Hee PARK, Eun Young KIM, Young Hoon KIM, Kwee Hyun SUH, Gwan Sun LEE
-
Publication number: 20090259047Abstract: The invention relates to crystalline barium salt of (S)-omeprazole, which is (S)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole. The invention also relates to processes for preparing crystalline barium salt of (S)-omeprazole and pharmaceutical compositions that include the crystalline barium salt of (S)-omeprazole so prepared.Type: ApplicationFiled: May 15, 2009Publication date: October 15, 2009Inventors: Yatendra KUMAR, Mahavir Singh Khanna, Mohan Prasad
-
Publication number: 20090253911Abstract: The present invention relates to an improved method for the synthesis of the (S)- or (R)-enantiomer of omeprazole, characterized in that 2-[[(4-X-3,5-dimethylpyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole or 2-[[(4-X-3,5-dimethyl-1-oxidopyridin-2-yl)methyl]thio]-5-methoxy-1H-benzimidazole, wherein X is a leaving group, is oxidized into the corresponding sulphoxide which is obtained as a crystalline compound. Recrystallisation of the thus obtained sulphoxide results in a compound of enhanced chemical and optical purity, which is subsequently transformed into the (S)- or (R)-enantiomer of omeprazole.Type: ApplicationFiled: December 5, 2008Publication date: October 8, 2009Inventors: Sverker von Unge, Christina Fregler
-
Patent number: 7598273Abstract: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.Type: GrantFiled: October 4, 2006Date of Patent: October 6, 2009Assignee: Auspex Pharmaceuticals, IncInventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7579476Abstract: The present invention is directed to a process for the catalytic oxidation of the thioether 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylthio)-1H-benzimidazole to its sulfoxide: 5-methoxy-2-((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)methylsulfinyl)-1H-benzimidazole comprising: reacting the thioether with: 1) a transition metal catalyst; and, 2) an oxygen source; wherein the thioether is oxidized to a sulfoxide and wherein one of either the R and S enantiomers is formed to an enantiomeric excess.Type: GrantFiled: May 15, 2006Date of Patent: August 25, 2009Assignee: Praktikatalyst Pharma, LLCInventors: Kenneth S. Wheelock, Louis A. Piccone
-
Publication number: 20090209592Abstract: Chemical syntheses and medical uses of novel inhibitors of the gastric H+, K+-ATPase for the treatment and/or management of duodenal ulcers, heartburn, acid reflux, other conditions mediated by gastric acid secretion and/or psoriasis are described.Type: ApplicationFiled: March 27, 2009Publication date: August 20, 2009Applicant: AUSPEX PHARMACEUTICALS, INC.Inventors: Thomas G. Gant, Sepehr Sarshar
-
Patent number: 7576219Abstract: This invention provides a crystalline S-omeprazole strontium hydrate for the prevention or treatment of gastric acid-related diseases, which has high optical purity, theremostability, solubility and nonhygroscopicity, a method for preparing same, and a pharmaceutical composition containing same.Type: GrantFiled: March 14, 2006Date of Patent: August 18, 2009Assignee: Hanmi Pharm. Co., LtdInventors: Tae Hee Ha, Hee Sook Oh, Won Jeoung Kim, Chang Hee Park, Eun Young Kim, Young Hoon Kim, Kwee Hyun Suh, Gwan Sun Lee